Source:http://linkedlifedata.com/resource/pubmed/id/15222105
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2004-6-29
|
pubmed:abstractText |
The purpose of this study was to examine the relation between tumoral expression of dihydropyrimidine dehydrogenase (DPD), the rate limiting enzyme of the degradation pathway 5-fluorouracil (5-FU), and the efficacy of 5-FU based chemotherapy for colorectal cancer. Twenty-eight colorectal cancer patients who had underwent noncurative resection (n = 16) or had developed recurrence (n = 12) were enrolled. All patients were given 5-FU plus leucovorin intravenously and UFT (1 M Tegafur, 4 M Uracil) perorally. The expression levels of the DPD in the primary lesions were determined by the enzyme-linked immunosorbent assay. Group A (n = 10) consisted of one patient with complete response, 4 with partial response, and 5 with no change (time to disease progression (TTP) > = 90 days). Group B (n = 18) consisted of 14 patients with progressive disease and 4 with NC (time to progression, < 90 days). The tumoral DPD levels did not differ between the groups (p = 0.58). There were no effective cases (n = 6) whose tumoral DPD levels were equal to or more than 83.2 U/mg protein (high DPD expression). There were marked overlaps in the DPD levels between the two groups whose DPD levels were less than 83.0 U/mg protein (moderate or low expression). These results suggest that high expression of tumoral DPD would be predictive to failure of fluoropyrimidine-based treatment. However, it is unlikely to set the optimal cutoff value for predicting the efficacy of this type of chemotherapy.
|
pubmed:language |
jpn
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Dihydrouracil Dehydrogenase (NADP),
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Leucovorin,
http://linkedlifedata.com/resource/pubmed/chemical/Tegafur,
http://linkedlifedata.com/resource/pubmed/chemical/UFT(R) drug,
http://linkedlifedata.com/resource/pubmed/chemical/Uracil
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0385-0684
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
31
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
883-7
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:15222105-Adult,
pubmed-meshheading:15222105-Aged,
pubmed-meshheading:15222105-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15222105-Colorectal Neoplasms,
pubmed-meshheading:15222105-Dihydrouracil Dehydrogenase (NADP),
pubmed-meshheading:15222105-Drug Administration Schedule,
pubmed-meshheading:15222105-Drug Combinations,
pubmed-meshheading:15222105-Female,
pubmed-meshheading:15222105-Fluorouracil,
pubmed-meshheading:15222105-Humans,
pubmed-meshheading:15222105-Leucovorin,
pubmed-meshheading:15222105-Male,
pubmed-meshheading:15222105-Middle Aged,
pubmed-meshheading:15222105-Tegafur,
pubmed-meshheading:15222105-Uracil
|
pubmed:year |
2004
|
pubmed:articleTitle |
[Tumoral dihydropyrimidine dehydrogenase expression and efficacy of 5-fluorouracil plus leucovorin plus UFT therapy in patients with colorectal cancer].
|
pubmed:affiliation |
Dept. of Surgery, Saitama Medical Center, Saitama Medical School.
|
pubmed:publicationType |
Journal Article,
English Abstract
|